Impact of Anti-Angiogenic Drugs on Severity of COVID-19 in Patients with Non-Small Cell Lung Cancer

A retrospective study involving 166 NSCLC patients with COVID-19 examined the impact of anti-angiogenic drugs on disease severity. Among the participants, 73 received anti-angiogenic therapy, while 93 did not. The study found no significant differences in severe/critical symptoms, ICU admission/intubation, or mortality between the two groups. However, factors such as age ≥ 60, poor performance status, chronic obstructive pulmonary disease, hypertension, and immunoglobulin use were associated with worse outcomes. The findings suggest that anti-angiogenic drugs do not worsen COVID-19 severity in NSCLC patients, supporting their safe use during the pandemic.